HCV burden in Europe and the possible impact of current treatment

Amin, 2006, Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study, Lancet, 368, 938, 10.1016/S0140-6736(06)69374-4 Corrao, 1998, Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis, Hepatology, 27, 914, 10.1002/hep.510270404 Gidding, 2010, Hospital-related morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia, Journal of Hepatology, 53, 43, 10.1016/j.jhep.2010.01.036 McDonald, 2011, Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006, Epidemiology and Infection, 139, 344, 10.1017/S0950268810001421 Mathurin, 1999, Impact of hepatitis B and C virus on kidney transplantation outcome, Hepatology, 29, 257, 10.1002/hep.510290123 Poynard, 1997, Natural history of liver progression in patients with chronic hepatitis C, Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8 Roudot-Thoraval, 1997, Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a french survey of 6664 patients, Hepatology, 26, 485, 10.1002/hep.510260233 Deuffic-Burban, 2012, Predicted effects of treatment for HCV infection vary among European countries, Gastroenterology, 143, 974, 10.1053/j.gastro.2012.05.054 McGarry, 2012, Economic model of a birth cohort screening program for hepatitis C virus, Hepatology, 55, 1344, 10.1002/hep.25510 Lettmeier, 2008, Market uptake of new antiviral drugs for the treatment of hepatitis C, Journal of Hepatology, 49, 528, 10.1016/j.jhep.2008.04.021 Delarocque-Astagneau, 2010, The impact of the prevention programme of hepatitis C over more than a decade: the French experience, Journal of Viral Hepatitis, 17, 435, 10.1111/j.1365-2893.2009.01196.x Jullien-Depradeux, 2002, National campaign against hepatitis C in France (1999–2002), Acta Gastroenterologica Belgica, 65, 112 Goldberg, 2008, Hepatitis C action plan for Scotland: phase II (May 2008–March 2011), Eurosurveillance, 13 Armstrong, 2000, The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States, Hepatology, 31, 777, 10.1002/hep.510310332 Davis, 2010, Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression, Gastroenterology, 138, 513, 10.1053/j.gastro.2009.09.067 Deuffic, 1999, Modeling the hepatitis C virus epidemic in France, Hepatology, 29, 1596, 10.1002/hep.510290528 Deuffic-Burban, 2008, Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France, Journal of Hepatology, 49, 175, 10.1016/j.jhep.2008.04.012 Mathurin, 1998, Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminases activity, Hepatology, 27, 868, 10.1002/hep.510270333 Deuffic-Burban, 2009, Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France, Hepatology, 50, 1351, 10.1002/hep.23159